Vise Technologies Inc. Purchases New Position in Illumina, Inc. $ILMN

Vise Technologies Inc. bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 5,181 shares of the life sciences company's stock, valued at approximately $911,000.

Other hedge funds have also bought and sold shares of the company. Empowered Funds LLC lifted its position in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of Illumina in the second quarter worth approximately $621,000. CW Advisors LLC bought a new stake in Illumina during the second quarter valued at approximately $275,000. Marshall Wace LLP grew its position in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock valued at $5,691,000 after buying an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC increased its holdings in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock valued at $706,000 after buying an additional 1,748 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. JPMorgan Chase & Co. increased their price target on shares of Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Illumina from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Evercore restated an "outperform" rating on shares of Illumina in a research note on Monday, July 6th. Citigroup upped their price target on shares of Illumina from $95.00 to $113.00 and gave the stock a "sell" rating in a research report on Monday, August 3rd. Finally, TD Cowen increased their price objective on shares of Illumina from $192.00 to $210.00 and gave the stock a "hold" rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $188.40.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Stock Performance

NASDAQ ILMN opened at $219.40 on Monday. The firm has a market cap of $33.13 billion, a price-to-earnings ratio of 40.93, a price-to-earnings-growth ratio of 3.09 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The business has a 50-day moving average price of $188.01 and a 200-day moving average price of $152.52. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $220.43.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the company earned $1.19 EPS. The firm's quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Activity at Illumina

In related news, Director Keith A. Meister sold 299,336 shares of the company's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the transaction, the director owned 1,409,851 shares in the company, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the firm's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares of the company's stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 2,095,958 shares of company stock valued at $401,720,974. Corporate insiders own 2.90% of the company's stock.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source